Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VAD044 is a once daily, orally administered, allosteric AKT inhibitor which has the potential to treat the underlying cause of Hereditary Haemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu Syndrome.
Lead Product(s): VAD044 L-Tartrate
Therapeutic Area: Genetic Disease Product Name: VAD044
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medicxi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022